Home » Topics » BioWorld Science, Conferences

BioWorld Science, Conferences
RSS

Brivanib alaninate is active as first- and second-line treatment in HCC patients

Sep. 10, 2009

Bevacizumab plus erlotinib therapy shows activity in phase II clinical trial in HCC

Sep. 9, 2009

New sensitive cardiac troponin assays may improve diagnosis of MI and ACS

Sep. 8, 2009

Phase II study suggests telmisartan may reverse epirubicin cardiotoxicity in cancer patients

Sep. 7, 2009

Potent dual orexin receptor antagonist SB-649868 shows hypnotic properties in multiple studies

Sep. 7, 2009

Novel beta-secretase 1 inhibitors developed by Schering-Plough for AD therapy

Sep. 7, 2009

Wyeth describes novel 5-HT2C receptor agonists with atypical antipsychotic activity

Sep. 4, 2009

Cangrelor prevents binding of clopidogrel and prasugrel active metabolites to P2Y12

Sep. 4, 2009

AZD-0837 effects on fibrin D-dimer levels and pharmacokinetics correlated in phase II study

Sep. 4, 2009

L-2286 attenuates myocardial hypertrophy in spontaneously hypertensive rats

Sep. 4, 2009

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 29, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for July 28, 2026
New schizophrenia targets challenge trial design
BioWorld
The search for better schizophrenia therapies is moving beyond dopamine toward a growing number of experimental targets. According to researchers, the repeated...
Regulatory actions for July 27, 2026
BioWorld
Regulatory snapshots for biopharma and med tech, including global submissions and approvals, and other regulatory decisions and designations: Alfasigma,...
AACR D3: ONM-421 shows antigen-independent tumor control
BioWorld Science
At the American Association for Cancer Research’s inaugural Drug Discovery and Development conference (AACR D3), Onconano Medicine Inc. presented preclinical data...